Is this you? As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.
Claim your profile
Back to Journals » Clinical Ophthalmology » Volume 20 Letter General Ophthalmology Authors Householder NA , Simonyan A Received 18 September 2026 Accepted for publication 22 September 2026 Published 2 October 2026 Volume 2026:20 657541 DOI https://doi.org/10.2147/OPTH.S657541 Checked for plagiarism Yes Editor who approved publication: Dr Sotiria Palioura Nicholas A Householder,1 Anahit Simonyan2 1Department of Ophthalmology and Visual Sciences, The University of Texas Medical Branch,...
Overview Background Long-duration thyroid eye disease (TED) may present with persistent proptosis despite the absence of inflammatory symptoms, and treatment options have been limited to surgical intervention. Recently, teprotumumab, a monoclonal antibody, has garnered interest as a non-surgical option to reduce proptosis in such cases. This systematic review investigates the impact of teprotumumab on reducing proptosis in long-duration TED.
As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.
